List view / Grid view
3 November 2015 | By Victoria White
Results from the study show that cabotegravir and rilpivirine were comparable in maintaining viral suppression rates to a three drug oral regimen...
3 November 2015 | By Coulter Partners
Coulter Partners was delighted to partner with German diagnostics company Curetis AG on two strategic supervisory board appointments and congratulates them on their recent IPO launch...
3 November 2015 | By Wickham Laboratories
Introducing the MALDI Biotyper® for rapid microbial identification....
3 November 2015 | By Black Swan Analysis
Black Swan Analysis has just been short-listed for the “The Management Team of the Year Award” sponsored by NatWest and open to outstanding management teams in the Thames Valley...
3 November 2015 | By Victoria White
The trial will evaluate GSK3174998 as monotherapy and in combination with Keytruda in patients with locally advanced, recurrent or metastatic solid tumours that have progressed after standard treatment...
3 November 2015 | By Victoria White
Shire has announced that it is to acquire Dyax, a company focused on the development of plasma kallikrein inhibitors for the treatment of hereditary angioedema, for approximately $5.9 billion...
3 November 2015 | By Victoria White
This is the third Breakthrough Therapy Designation granted for Keytruda. The drug was previously granted breakthrough status for advanced melanoma and advanced non-small cell lung cancer (NSCLC)...
3 November 2015 | By Victoria White
The acquisition will give Bristol-Myers Squibb full rights to Cardioxyl’s lead asset CXL-1427...
3 November 2015 | By Victoria White
The Breakthrough Therapy Designation was granted based on results from an extension cohort of a Phase 1 study that assessed the safety and efficacy of pexidartinib...
3 November 2015 | By Victoria White
BI 1482694 is a novel, third-generation, oral, irreversible EGFR mutant-specific tyrosine kinase inhibitor (TKI) developed to specifically target tumours with T790M mutations...
30 October 2015 | By Victoria White
Bayer plans for an immediate introduction of Eylea to the market with Germany being one of the first launch countries in Europe...
30 October 2015 | By Victoria White
The Phase 2 study is intended to further characterise the profile of ISIS-FXI Rx and will provide essential data for Bayer's future clinical development programme for ISIS-FXI Rx...
30 October 2015 | By Victoria White
CL-108 is being developed as a treatment for moderate to severe pain and the prevention of opioid-induced nausea and vomiting (OINV)...
30 October 2015 | By Victoria White
Dr Hervé Dombret says the 'announcement brings hope to patients with AML, particularly the elderly and more frail patients who cannot undergo intensive therapies'...
29 October 2015 | By Victoria White
The global multiple myeloma treatment market will rise in value from $8.9 billion in 2014 to an estimated $22.4 billion by 2023, according to research and consulting firm GlobalData...
